| |
 |
|
|
Michael Y. Chen, M.D., Ph.D.
Department of Neurosurgery
City of Hope National Medical Center
EDUCATION AND TRAINING:
Medical School:
Pennsylvania State University and Thomas Jefferson University
Board Certification:
Neurosurgery
SUMMARY:
Dr. Michael Y. Chen, M.D., Ph.D., joined our faculty as an assistant professor of
neurosurgery in January 2007. Dr. Chen has particular interest in the treatment of
primary and metastatic disease of the brain and spine, and is actively co-leading the
establishment of a new spine program.
As a researcher, Dr. Chen has authored or co-authored over 30 original papers, abstracts and
book chapters covering novel genetic and biomedical engineering approaches for the
treatment of central nervous system diseases. Dr. Chen focuses his research efforts on
examination of individualized therapy for glioblastoma patients based the treatment response
of surrogate rodent models, and intraoperatively delivered T-cell immunotherapy for metastatic
brain tumors for which a clinical trial is currently in the preparatory stages. In the lab his interests
include catheter-guided intraparenchymal delivery of small molecule inhibitors, viral and
non-viral gene therapy vectors for the treatment of metastatic brain tumors.
Dr. Chen comes to the City of Hope from the Virginia Commonwealth University
Hospitals, where he served as an assistant professor. He attended a combined B.S./M.D.
program at Pennsylvania State University and Thomas Jefferson University (1996).
Between his second and third years of medical school, Dr. Chen obtained a masters
degree in biomedical engineering from the John Hopkins University (1994). After a
surgical internship, again at Johns Hopkins, he became a research fellow at the Surgical
Neurology Branch of the National Institutes of Health, where studied nanoparticle and
viral gene delivery using high-flow micro-infusion. Dr. Chen then performed his
neurosurgical residency at the Virginia Commonwealth University Hospitals. During this
time, he also obtained his Ph.D., which examined the effect of Wilms' Tumor 1 silencing
on glioblastoma programmed cell death. |
